Impact of high neutrophil‐to‐lymphocyte ratio on survival in hospitalized cancer patients with COVID‐19

Neutrophil‐to‐lymphocyte ratio (NLR) has been studied as a prognostic factor for mortality in COVID‐19 patients. Our study aimed to evaluate the association between NLR at COVID‐19 diagnosis and survival during the following 90 days in hospitalized patients with solid cancer. Between May 2020 and Ju...

Descripción completa

Detalles Bibliográficos
Autores principales: Díaz‐Couselo, Fernando A., Flagel, Santiago, Nicolini, Carla, Halac, Sebastián, Manzano, Natalia, Aguirre, Marina, Rébora, Juan, Valle, Sandra, Noro, Laura, Mohindroo, Chirayu, McAllister, Florencia, Zylberman, Marcelo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
BRIEF COMMUNICATION
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9877941/
https://www.ncbi.nlm.nih.gov/pubmed/36372937
http://dx.doi.org/10.1002/cam4.5426
Descripción
Sumario:Neutrophil‐to‐lymphocyte ratio (NLR) has been studied as a prognostic factor for mortality in COVID‐19 patients. Our study aimed to evaluate the association between NLR at COVID‐19 diagnosis and survival during the following 90 days in hospitalized patients with solid cancer. Between May 2020 and June 2021, 120 patients were included in a retrospective cohort study. Univariable analysis showed patients with an NLR > 8.3 were associated with an increased risk of death (HR: 4.34; 95% CI: 1.74–10.84) compared to patients with NLR < 3.82 and with NLR ≥3.82 and ≤8.30 (HR: 2.89; 95% CI: 1.32–6.36). Furthermore, on multivariable analysis, NLR > 8.30 independently correlated with increased mortality. In patients with solid malignancies with COVID‐19, an NLR > 8.3 is associated with an increased risk of death.

Ejemplares similares